Sonrotoclax
- Generic Name
- Sonrotoclax
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Phase 3
Not yet recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 630
- Registration Number
- NCT06943872
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1
Not yet recruiting
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Nodal Marginal Zone LymphomaRecurrent Splenic Marginal Zone Lymphoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire Administration
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT06859008
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
BRAZAN Trial in Frontline MCL
Phase 2
Not yet recruiting
- Conditions
- Mantle Cell LymphomaLymphoma
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Christine Ryan
- Target Recruit Count
- 60
- Registration Number
- NCT06854003
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients with CLL or SLL
Phase 2
Not yet recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06849713
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Chronic Lymphocytic LeukemiaMantle Cell LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Mantle Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Mantle Cell LymphomaRefractory Small Lymphocytic LymphomaSmall Lymphocytic Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Gastrointestinal Endoscopy
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06839053
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
Phase 3
Recruiting
- Conditions
- Mantle Cell LymphomaB Cell Lymphoma
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT06742996
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny Nr W Lublinie, Lublin, Poland
🇺🇸University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Phoenix, Phoenix, Arizona, United States
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Phase 1
Recruiting
- Conditions
- Chronic Lymphocytic LeukemiaCLL
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 56
- Registration Number
- NCT06697184
- Locations
- 🇫🇷
Hopital Larchet Chu Nice, Nice, France
🇫🇷Iuct Oncopole, Toulouse, France
🇫🇷Hopital Avicenne, Aphp, Bobigny, Bobigny, France
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Phase 2
Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 87
- Registration Number
- NCT06637501
- Locations
- 🇵🇱
Pratia McM Krakow, Krakow, Poland
🇵🇱Pratia Onkologia Katowice, Katowice, Poland
🇺🇸University of Miami, Miami, Florida, United States
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1
Recruiting
- Conditions
- B-cell MalignancyRelapsed CancerRefractory CancerB-cell Lymphoma
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 80
- Registration Number
- NCT06634589
- Locations
- 🇮🇹
Centroricerche Cliniche Di Verona Srl, Verona, Italy
🇺🇸Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸University of Southern Californianorris Comprehensive, Los Angeles, California, United States
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Not Determined
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT06543043
- Locations
- 🇺🇸
Quotient Sciences, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath